<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02471105</url>
  </required_header>
  <id_info>
    <org_study_id>S57304</org_study_id>
    <nct_id>NCT02471105</nct_id>
  </id_info>
  <brief_title>Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml</brief_title>
  <acronym>SPORTII</acronym>
  <official_title>IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a
      clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A prospective, randomized, investigator-masked, crossover comparison;

        -  Ocular hypertension or glaucoma (XFG or POAG) patients and who consent to participate
           will be enrolled in this study

        -  Patients will be scheduled for a screening visit IOP assessment (IOP measurements at
           08:30, 12:30 and 16:30 (±1 hour).

        -  Patients who are on therapy at the screening visit and who consent to participate will
           undergo a washout period for 4 weeks (depending on therapy) before the baseline visit;

        -  Patient can under the washout period be given brinzolamide (Azopt) if needed, Azopt
           should then be discontinued 5 days before baseline visit;

        -  After the screening visit (and after wash-outperiod for treated patients) patients will
           be scheduled to undergo a baseline visit IOP assessment (IOP measurements at 08:30,
           12:30 and 16:30 (± 1 hour with a minimum of 3 hours between readings) and will then be
           randomized for Period 1 to receive either BIMMD drops once in the evening (20:30) or
           TUDPF drops once in the evening (20:30) for 3 month

        -  After 3 month, patients will be switched for Period 2, to the opposite treatment (e.g.
           switched to either BIMMD or TUDPF) to be dosed in the evening;

        -  After another 3 months they will undergo the final evaluation of IOP levels and of
           tolerability;

        -  Intermediate safety visits may be scheduled at the discretion of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in mean IOP values between the 2 groups</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference in IOP values between the groups in change from baseline IOP</measure>
    <time_frame>month 3 and month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference in mean IOP between the 2 groups</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the difference in IOP between the 2 groups at each timepoints</measure>
    <time_frame>month 3 and month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Lumigan 0.01% + Saflutan 15 µg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saflutan 15 µg/ml + Lumigan 0.01%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preserved Bimatoprost 0.01%</intervention_name>
    <description>Eye drops solution Topical use Once in the evening 3 months</description>
    <arm_group_label>Lumigan 0.01% + Saflutan 15 µg/ml</arm_group_label>
    <arm_group_label>Saflutan 15 µg/ml + Lumigan 0.01%</arm_group_label>
    <other_name>BIMMD</other_name>
    <other_name>Lumigan 0.01 %</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafluprost Unit Dose Preservative Free 15microgram/ml</intervention_name>
    <description>Eye drops solution Topical use Once in the evening 3 months</description>
    <arm_group_label>Lumigan 0.01% + Saflutan 15 µg/ml</arm_group_label>
    <arm_group_label>Saflutan 15 µg/ml + Lumigan 0.01%</arm_group_label>
    <other_name>TUDPF</other_name>
    <other_name>Saflutan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient suffering from ocular hypertension, XFG or POAG and needs treatment in both
             eyes

          -  Patient is at least 18 years

          -  Patient is able and willing to participate in the study for the whole duration of the
             follow up and is willing to sign the consent form.

        Exclusion Criteria:

          -  Unwilling to sign informed consent;

          -  Younger than 18 years old;

          -  Ocular condition that are of safety concern and that can interfere with the study
             results;

          -  Visual field defects with an MD value above -15dB on either eye on Humphrey (or the
             equivalent in Octopus) and/or threatening fixation

          -  Contact lens wearer;

          -  Closed/barely open anterior chamber angles or history of acute angle closure on either
             eye as assessed by gonioscopy;

          -  Ocular surgery (other than glaucoma surgery) or argon laser trabeculoplasty within the
             past three months on either eye;

          -  Glaucoma surgery within the past 6 months on either eye;

          -  Ocular inflammation/infection occurring within three months prior to pre-trial visit
             on either eye;

          -  Concomitant topical ocular medication that can interfere with study medication on
             either eye;

          -  Known hypersensitivity to any component of the trial drug solutions;

          -  Other abnormal condition or symptom preventing the patient from entering the trial,
             according to the Investigator's judgement;

          -  Refractive surgery patients at any time;

          -  Women who are pregnant, are of childbearing potential and are not using adequate
             contraception or are nursing;

          -  Inability to adhere to treatment/visit plan;

          -  Have participated in any other Interventional clinical trial (i.e., requiring informed
             consent) involving an investigational drug within one month prior to pre-trial visit.

          -  History of COPD, asthma or heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingeborg Stalmans, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingeborg Stalmans, Phd</last_name>
    <phone>003216332372</phone>
    <email>ingeborg.stalmans@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sien Boons</last_name>
    <phone>0032163340391</phone>
    <email>sien.boons@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hommer Ophthalmology Institute</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Hommer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingeborg Stalmans, Phd</last_name>
      <phone>003216332372</phone>
      <email>ingborg.stalmans@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Sien Boons, Optometrist</last_name>
      <phone>003216340391</phone>
      <email>sien.boons@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>San Paolo Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Rossetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bietti Foundation</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>francesco Oddone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre Momorial A. de Rotschild</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gordana Megevand</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Gloucestershire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew McNaught</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Cordeiro</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2015</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

